Articles On Paradigm Biopharmaceuticals (ASX:PAR)

Sonic Healthcare to buy LADR – Laboratory Group Dr. Kramer & Colleagues in Germany for ~A$700 million ASX health stocks fall 2.3% over past five days, while the broader market fell ~1.5%  Chemist Warehouse could list on the ASX by earl...

Opyl has partnered to form the ‘world’s first’ AI-driven biotech fund Visioneering sees a brighter future – elsewhere – but its shares tumble  Cyclopharm breathes easy after decent lung transplant trial results   Who needs fund managers t...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small decline. At the time of writing, the benchmark index is down almost 0.2% to 8,407 points. Four ASX shares that are falling more than most today are lis...

Paradigm Biopharmaceuticals Ltd (ASX: PAR) shares are starting the week deep in the red. In morning trade, the ASX healthcare stock is down 26% to 43 cents. Why is this ASX healthcare stock crashing deep into the red? The catalyst for today...

Investors that have a high tolerance for risk might want to consider the small cap ASX shares in this article. That's because they have just been named as buys with major upside potential. Here's what analysts are saying about them: Ai-Med...

ASX healthcare stock Paradigm Biopharmaceuticals Ltd (ASX: PAR) has been on a strong run in the past month, soaring 160%. But the drug development company has requested a pause in the trading of its shares before the open on Thursday....

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

The S&P/ASX 200 rose 4% in November to a new record high of 8436.23 points as volatility fell following US election Information Technology led the gainers rising 10% in November and remained top performer YTD, up 56.79%  NoviqTech rose...

If you have a high tolerance for risk, then read on! That's because the two small cap ASX shares listed below have just been named as buys and tipped to rise strongly from current levels. Here's what brokers are saying about these shares:...

This week’s Bulls N’ Bears Runner of the Week is … PhosCo. The African phosphate explorer nabbed a vital exploration permit, while Paradigm Biopharmaceuticals, AV Jennings and Errawarra Resources also ran hard.

Good afternoon, a happy end of the week, and welcome to HotCopper Highlights – I’m Jonathon Davidson.  Let’s get into it. Perth Basin gas developer Strike Energy commanded 13, 205 eyes on Thursday with its news the company will go ahe...

ASX hits new record high, driven by banks and health stocks Pro Medicus signs $330m deal with Trinity Health Lithium stocks rise on WA government’s $150m support package   The ASX touched a new record high on Thursday, the second time thi...

US FDA successfully concludes 30-day review of Paradigm Biopharmaceuticals phase III trial protocol Pivotal trial of repurposed pentosan polysulfate sodium (Zilosul) to treat knee osteoarthritis due to start in Q1 CY25 Paradigm to progress...

Paradigm Biopharmaceuticals Ltd (ASX: PAR) shares started the week with an almighty bang. The ASX biotech stock ended the session almost 42% higher at 46 cents. At one stage, the biopharmaceutical company's shares were up as much as 52% to...

Painchek is eyeing a market of 1.7 million US aged-care beds for its pain-detection device Genetic Signatures sizes up a $400 million US market The latest thrills and spills at life sciences AGMs   PainChek (ASX:PCK) lodged a US Food &amp...

Sonic reaffirms earnings guidance and says it is on the hunt for “sensible” acquisitions Boards face their inquisitors in peak AGM week Resonance shares soar on Sun Pharma deal   Pathology and radiology giant Sonic Healthcare (ASX:SHL) sa...

The ASX200 closed down 0.25% at 8,160 points. Gold climbed to a record high as investors engaged in a flight to safety. Demand for goal has soared in the week before the U.S. election and reached US$2790 per ounce. IT was the biggest...

  ASX slips  amid earnings updates and company meetings AGL drops over 6pc after downgrade, while Origin Energy rises Talga surges after Sweden approves graphite mine   The ASX slipped by 0.22% after being dragged by a flurry of company...

Two S&P/ASX All Ordinaries Index (ASX: XJO) ASX healthcare shares are making big moves today following the release of their quarterly performance updates. One is racing ahead of the 0.2% losses posted by the All Ordinaries Index (ASX: X...

The ASX may dip as Wall Street fell overnight Meta’s projections disappointed investors, while Microsoft delighted Super Micro’s stock plummeted 33pc after its auditor resigned   The ASX is expected to dip a bit after Wall Street closed l...

Biocurious is renowned healthcare and biotech journalist Tim Boreham’s weekly deep dive into the complex, challenging and often inspiring world of medtech innovation on the ASX.    Paradigm shares are trading near record lows despite good...

Paradigm Biopharmaceuticals says it is ready to apply to the US regulator to start its delayed phase III trial for knee osteoarthritis AFT Pharmaceuticals has entered a deal with two European partners to develop a secret novel drug PYC The...

EBR has developed the WiSE Cardiac Resynchronization Therapy (CRT) system, the world’s first leadless pacing system for heart failure Trytamine Therapeutics is pioneering a precision approach to psychedelics, targeting precise drug blood l...

Australia’s clinical trials sector generated $1.6bn for the nation’s economy in 2022 according to MTPConnect PharmAust is currently undertaking a Phase 1 open label extension study at two sites in Australia Dimerix has seven Australian sit...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Sarah Hughan tells all on Paradigm Biopharmaceuticals’ (ASX:PAR) support from the US Food and Drug Administration, paving the way fo...

Recent updates highlight significant strides in the biopharmaceutical sector. Paradigm Biopharmaceuticals Ltd has received FDA feedback on its Phase III osteoarthritis study. Actinogen Medical Ltd has secured funding for its Alzheimer’s tri...

The ASX200 closed up 0.02% at 8,142 points in a flat days trade. Australian shares broke an intra-day record during a volatile day, as investors await the US Fed rate decision due tomorrow Australian time. The big iron ore miners pare...

  ASX slips after hitting new high ahead of Fed decision Iron ore prices expected to drop below US$80 by 2025 Harvey Norman faces class action lawsuit over warranties   The ASX was a bit of a mixed bag today, hitting a new high before pu...

Paradigm receives positive response from US FDA for progression of Phase 3 trial FDA confirmed its Phase 2 trial data supported safety and tolerability of twice weekly 2mg/kg dosage Once updated protocol is submitted to FDA, Paradigm anti...

Health Check (briefly called Alive and Kicking before we grew tired of the Simple Minds tune running through our noggins) is renowned biotech journo Tim Boreham’s NEW daily wrap covering morning movers and shakers of note in the ASX Healthc...

Paradigm Biopharmaceuticals Ltd (ASX: PAR) shares are taking off on Wednesday. In morning trade, the ASX biotech stock is up 11% to 29 cents. Why is this ASX biotech stock surging? Investors have been buying the late-stage drug development...

Paradigm Biopharmaceuticals (ASX:PAR) has confirmed that it will use a twice weekly dosage of 2mg/kg injectable pentosan polysulfate sodium (iPPS) in its looming Phase 3 knee osteoarthritis trial in the US. PAR lodged a ‘Type D meeting r...

ASX set to drop ahead of US Fed Reserve rate cut decision Oil prices rise 1.5pc due to Gulf of Mexico production disruptions Bitcoin surges on expectations of lower interest rates   The ASX is set to drop on Wednesday, following a muted s...

Dimerix chief Dr Nina Webster describes the three stages of drug development and the hurdles involved Dimerix is in phase III trials to treat a rare kidney condition Following promising interim analysis, further results are expected in mid...

For biotech investors, the news of an approval by the US FDA is a genuinely exciting milestone. The FDA is the ultimate gatekeeper for the US pharmaceutical market, which is by far the world’s largest. Approval from the FDA not only validat...

Last Monday marked Clinical Trials Day, when the world’s healing profession celebrated the work of Royal Navy surgeon James Lind. The medical mariner was credited with carrying out the world’s first placebo-controlled clinical trial in 1747...

Imricor has two upcoming pivotal trials and is looking to transform cardiac ablation procedures  Botanix Pharmaceuticals is expecting US FDA approval for its lead dermatology product Sofdra in late June Bell Potter is confident in Paradigm...

Paradigm Biopharmaceuticals Ltd (ASX: PAR) shares could have huge upside potential. That's the view of analysts at Bell Potter, which believe the ASX biotech stock could be a great option for investors with a high tolerance for risk. What i...

S&P/ASX 200 Health Care (ASX: XHJ) shares are up 0.44% on Tuesday while the ASX 200 is up 0.23%. But these three ASX healthcare shares are knocking it out of the park on this otherwise lacklustre day. Here's why. Paradigm Bio...

The S&P/ASX 200 Index (ASX: XJO) is having another day to forget on Friday. In afternoon trade, the benchmark index is down 1.45% to 7,532.3 points. Four ASX shares that are not letting that hold them back today and are avoiding the ma...

Paradigm submits key documents to US FDA to advance its pivotal Phase 3 trial of iPPS/Zilosul Biotech also submits a draft of protocol for the Phase 3 pivotal clinical trial to FDA for review and comment Pending FDA clearance, PAR aims to...

Paradigm Biopharma submits response to the FDA INOVIQ says its blood test on cancer is highly accurate   Paradigm sends response to the US FDA Paradigm Biopharmaceuticals (ASX:PAR) announced that it has submitted important documents to t...

Paradigm Biopharma (ASX:PAR) has announced its completion of a submission to the US FDA to progress to Phase III of its osteoarthritis treatment ‘program.’ Within the application Paradigm bundled the results of five nonclinical studies a...

  ASX to fall on Friday on the back of strong US jobs report Netflix down 5pc after reporting Q1 results Bitcoin halving to happen today or tomorrow   Aussie shares are set to fall on Friday after the US released another strong jobs repo...

Several ASX companies are repurposing or resurrecting abandoned or under utilised drugs  Paradigm Biopharmaceuticals identified the potential of FDA-approved PPS that has a long track record of treating inflammation Starpharma has develope...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Every country worldwide is seeing growth in both size and percentage of older people in their population Lodge Partners says anti-aging and longevity has become a focus area for pharmaceutical and biotech companies LTR Pharma is helping ol...

Paradigm Biopharma’s Phase 2 meets primary endpoint TrivarX collaborates with US university to advance sleep research   Paradigm’s successful Phase 2 trial Paradigm Biopharma (ASX:PAR) announced that its Phase 2 clinical trial, PARA_MPSVI...

Research reports on ASX-listed companies, to download in full. **** -Actinogen Medical ((ACW)) by Research as a Service (RaaS): https://www.fnarena.com/index.php/download-article/?n=2B537F21-A3D7-CB04-98294578CBAE8E12 -Amaero International ...

Tim Boreham highlights the success of Paradigm Biopharmaceuticals' joint pain drug ahead of a capital raising. by Tim Boreham ASX code: ((PAR)) Share price: 41.5c Shares on issue: 281,756,625 (pre capital raise) Market cap: $116.9 m Executi...